Anavex Life Sciences Corp (AVXL)

[bb8675309]

'crescentmotor'

Wow--that would make the Street grossly inefficient, which is often the case. I think that $5 billion is unreasonable for three indications, one of which has passed Phase 3. It's hard to believe AVXL is sitting at $10 even with the Street currently sitting on biotech valuations. Surely AVXL will be in the $35-$50 range before 2023 assuming further trial success in Parkinson's and AD?

AVXL has demonstrated years of continuous proof of positive drug trial results in the CNS space. No company has done this to current date. Premiums accrued.